North America Multiplexed Diagnostics Market Report and Forecast 2024-2032

North America Multiplexed Diagnostics Market Outlook

The global multiplexed diagnostics market size was valued at USD 12.9 billion in 2023, with North America holding a substantial market share. The market is driven by the advancements in multiplexing technologies. It is expected to grow at a CAGR of 15.2% during the forecast period of 2024-2032, with the values likely to attain USD 46.2 billion by 2032.

Key Takeaways

• Nearly half of Americans have some type of heart disease and 1 in 5 deaths in the United States are caused by heart disease annually. Multiplexed diagnostics can be used to attain actionable health insights for cardiovascular disease patients in less time and cost.

• The introduction of technologically advanced multiplexed diagnostic platforms is assisting clinicians in delivering rapid treatment to patients, which is likely to boost the North America multiplexed diagnostics market share. In February 2024, PathogenDx, launched D3 Array™-UTI, a multiplexed molecular diagnostic technology based on PathogenDx's patented Dynamic Dimensional Detection (D3 Array™) to quickly detect urinary tract infection and antibiotic resistance.

• One of the major market trends is the increased funding from government organizations to advance diagnostic technologies. In April 2023, Sapphiros AI Bio received USD 11.1 million from a National Institutes of Health (NIH) initiative to develop an over the counter (OTC) multiplex molecular respiratory diagnostic test.

North America Multiplexed Diagnostics Market Analysis

Multiplexing is characterized by the simultaneous detection or identification of multiple biomarkers in a single diagnostic test. Multiplexed detection of biomarkers in certain diseases helps in accurately diagnosing the patient, as well as selecting the appropriate therapy. Thus, multiplexed diagnostic methods improve patient outcomes along with decreasing associated healthcare costs. Further, advancements in these techniques have led to increased efficiency and output, resulting in higher adoption in clinical laboratories and boosting North America multiplexed diagnostics market growth.

The rise in chronic disease burden including cardiovascular diseases and cancer positively impacts the market size. Recent data suggests that nearly half of Americans have some type of heart disease . Moreover, 1 in 5 deaths in the United States are caused by a heart disease annually. Multiplexed diagnostics can prove to be valuable in getting actionable health insights for cardiovascular disease patients in lesser time and cost. The multiplex detection of relevant biomarkers can not only reveal the pathophysiology of the disease but also help in picking the most effective treatment plan, thereby, propelling the North America multiplexed diagnostics market demand.

In April 2023, Sapphiros AI Bio, a United States-based computational biology company announced its selection in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) program, receiving USD 11.1 million as part of the NIH initiative to develop an over the counter (OTC) multiplex molecular respiratory diagnostic test. The firm intends to use the funds to design an easy-to-use, affordable, and rapidly deployable diagnostic method for the detection of influenza A, influenza B, respiratory syncytial virus (RSV), and COVID-19 in a single test. The increased investment from various sectors to advance diagnostic technologies, particularly government initiatives that offer robust financial aid, are expected to augment North America multiplexed diagnostics market share.

In February 2024, PathogenDx, a next-generation microarray technology provider based in Arizona, United States, launched D3 Array™-UTI, a multiplexed molecular diagnostic technology based on PathogenDx’s patented Dynamic Dimensional Detection (D3 Array™) to detect urinary tract infection and antibiotic resistance. The multiplexed PCR test, with automated data analysis and reporting, can detect 26 pathogens and 12 antibiotic resistance gene markers, thereby advancing UTI diagnosis, and improving patient outcomes. The introduction of such technologically advanced multiplexed diagnostic platforms that can assist clinicians in delivering rapid treatment to patients is poised to significantly elevate the market value in the forecast period.

North America Multiplexed Diagnostics Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

North America Multiplexed Diagnostics Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Thermo Fisher Scientific Inc.

• Agilent Technologies

• BioMerieux SA

• Bio-Rad Laboratories

• Illumina, Inc.

• F. Hoffmann-La Roche Ltd.

• Hologic, Inc.

• Qiagen N.V.

• Siemens Healthineers

• Luminex Corporation

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report